Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 17

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

24 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
27.08.2026journal-article

Molecules

Cytotoxic Triterpenes from Argan Pulp (Argania spinosa): Isolation, In Vitro Evaluation on Cancer Cell Lines, and In Silico Studies

Asma El Kaourat, Badr Eddine Kartah, Mohamed El Fadili, Noura Bentarhlia, Hamza Tachallait, Yassine Jaouhari, Matteo Bordiga, Zineb Ourradi, Younes Zaid, Zoubida Charrouf, Hanae El Monfalouti

This study focuses on the isolation, characterization, and evaluation of cytotoxicity of triterpenes extracted from argan pulp. The unsaponifiable lipids extracted from argan pulp are separated into five fractions, two of which are triterpene fractions F2 (composed of α-amyrin, β-amyrin, lupeol, ψ-taraxasterol, taraxasterol) and F4 (erythrodiol). The extraction process utilized solvent-based methods followed by purification through column chromatography. Structural elucidation was carried out using GC-MS and NMR te …

27.08.2026journal-article

BMJ Supportive & Palliative Care

Objective assessment of activities of daily living and prognosis in patients with terminal cancer in the palliative care unit: a retrospective cohort study

Shunsuke Nakanishi, Riki Sakata, Ayaka Nishimura, Keiko Onishi, Tomoo Okumura, Yasushi Miura

Objectives Rehabilitation in patients with terminal cancer plays an essential role in maintaining quality of life. However, limited consensus exists regarding rehabilitation in the palliative care unit (PCU). This study aimed to support the setting of appropriate goals in the rehabilitation of patients with terminal cancer in a PCU. Methods In this retrospective cohort study, 224 patients with terminal cancer admitted to a PCU were analysed. Participants were classified based on total Functional Independence Measur …

27.08.2026journal-article

Current Oncology Reports

Role of Interventional Oncology in the Management of Neuroendocrine Tumors: 2026 Update

Daniel M. DePietro, Michael C. Soulen

Abstract Purpose of Review Summarize recent advances in interventional oncology for the management of neuroendocrine tumor liver metastases (NETLMs), with a focus on evolving evidence for embolization and ablation, integration with systemic therapies, and emerging approaches. Recent Findings Recent studies have strengthened the role of liver-directed therapies within multidisciplinary NET care. Long-term data supports transarterial chemoembolization as an effective and repeatable line of therapy. Improved dosimetry …

27.08.2026journal-article

Diagnostics

Digital Patient-Reported Monitoring of Functional Recovery After Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer Treated With or Without Perioperative Hormonal Therapy

Bogdan Adrian Buhas, Alessandro Uleri, Giorgio Calleris, Guilhem Roubaud, Marine Lesourd, Benjamin Pradère, Christophe Tollon, Damien Pouessel, Bernard Malavaud, Loïc Mourey, Guillaume Ploussard

Background/Objectives: Perioperative androgen-deprivation therapy (ADT) and androgen-receptor pathway inhibitors (ARPIs) are increasingly used in high-risk prostate cancer, yet patient-centred functional-recovery data after radical prostatectomy are scarce and rarely standardized. We assessed whether a smartphone-based digital monitoring pathway could characterize social-continence recovery and capture differences associated with a perioperative hormonal therapy (PHT) strategy after robot-assisted radical prostatec …

27.08.2026journal-article

Cell Communication and Signaling

SIRT3 determines the sensitivity of cancer cells to mitochondrial targeting

Maria A. Yapryntseva, Matvey A. Vinogradov, Pavel I. Volik, Anastasiia V. Melnikova, Sofia E. Kiseleva, Anastasiya V. Poteryakhina, Alexey V. Zamaraev, Gelina S. Kopeina, Boris Zhivotovsky, Vladimir Gogvadze

Abstract SIRT3 is a mitochondria-localized member of the sirtuin family, playing a key role in cellular antioxidant defense. Its function in carcinogenesis and therapy response remains uncertain. In the present study, we sought to identify the role of SIRT3 in regulating cell death induced by conventional DNA-damaging anticancer drugs or mitochondria-targeting compounds using bioinformatic analysis, western blot analysis, viability, and clonogenic assays. High SIRT3 levels were associated with higher sensitivity to …

27.08.2026journal-article

Neuro-Oncology

71 Hypertrophic olivary degeneration after dentate nucleus involvement in two patients with Central Nervous System Lymphoma: a potential mimic of relapse

Valentina Fenech, Laura Preston, Emanuela Molinari

Abstract Introduction Hypertrophic olivary degeneration (HOD) is a rare transsynaptic degeneration caused by disruption of the Guillain-Mollaret triangle. In neuro-oncology, it may mimic tumour recurrence, particularly during post-treatment surveillance of posterior fossa disease. We describe two cases of contralateral HOD following dentate nucleus involvement in central nervous system lymphoma (CNSL), highlighting an important diagnostic pitfall. Method We reviewed clinical, radiological and follow-up data from tw …

27.08.2026journal-article

Neuro-Oncology

6 Radiogenomics of circumscribed versus diffuse grade 4 gliomas based on standard molecular markers

Adnan Hammad, John McNamee, Tom Flannery

Abstract Introduction The two main types of adult grade 4 gliomas are IDH1-wildtype glioblastomas and IDH-mutant astrocytomas. Each have their own molecular hallmarks. We sought to determine if there are differences in molecular markers between radiologically circumscribed and diffuse grade 4 gliomas. Method We carried out a retrospective analysis of a single surgeon’s experience of adult patients undergoing surgery for grade 4 gliomas at our institution between January 2019 and July 2024. Results We identified 145 …

27.08.2026journal-article

Genes

Integrating Multi-Omics and Machine Learning to Reveal a Prognostic Model for Prostate Cancer Metastatic Recurrence Associated with Epithelial–Mesenchymal Transition Features

Xueqian Zhang, Wei Zhang, Zheng Wang, Xinyang Shi, Chenghao Zhang, Yan Gao, Yiheng Deng, Tianyu Shen, Ziyan An, Weijun Fu

Background: Prostate cancer (PCa) is a leading cause of cancer-related mortality worldwide, highlighting the need for improved prognostic tools. The integration of artificial intelligence (AI) and machine learning (ML) with multi-omics data offers new opportunities for biomarker discovery and risk stratification. Methods: We integrated bulk transcriptomic data from GSE116918 (training, n = 248) and three cross-cohort consistency evaluation cohorts (TCGA-PRAD, GSE70769, GSE46602), focusing on 1087 epithelial–mesench …

27.08.2026journal-article

The Oncologist

Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study

Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, Xinpei Yu, Guanming Jiang

Abstract Background The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors. However, concurrent mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma and combination therapies may offer a superior approach. This study explores the efficacy and safety of osimertinib plus anlotinib as first-line treatment for advanced NSCLC with EGFR co-mutations. Materials and Methods This study prospectively enrolled patients with adva …

27.08.2026journal-article

Journal of Clinical Medicine

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

Esra Asarkaya, Hatice Asoglu, Abdurrahman Aykut, Gunes Dorukhan Cavusoglu, Yasemin Aydınalp, Sendag Yaslıkaya, Suheda Atas Ipek, Fatma Calkan, Emine Kilic Bagir, Derya Gumurdulu, Hulya Binokay, Tolga Koseci, Ismail Oguz Kara, Berksoy Sahin, Ertugrul Bayram

Background: Lung cancer remains the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Over the past decade, immune checkpoint inhibitors have become a core component of first-line treatment for advanced-stage NSCLC lacking driver mutations. Programmed death-ligand 1 (PD-L1) expression is currently used as the standard biomarker, yet its predictive value remains limited, and in most immunotherapy trials, treatment efficacy has been observed …

27.08.2026journal-article

Neuro-Oncology

53 Analysis of translational challenges across 19 brain tumour therapeutic development programmes: Insights from the BTR-NTA accelerator

Kate Munro, Eloise Lines, Nicky Huskens, Katie Bushby, Karen Noble, Paul Brennan, Helen Bulbeck, Petra Hamerlik, Darren Hargrave, Edward Kaye, Dione Kobayashi, Ryan Mathew, Javad Nazarian, Ruman Rahman, Artie Romero, Erik Sulman, Juanita Lopez, Kanneboyina Nagaraju

Abstract Introduction Development of novel therapies for brain tumours faces high attrition rates, with few programmes reaching approval. This thematic analysis synthesises translational challenges identified through the Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA), an international multidisciplinary programme providing structured expert guidance to accelerate novel brain tumour treatments toward clinical application. Methods Between 2023 and 2025, BTR-NTA received 33 applications from academic an …

27.08.2026journal-article

Neuro-Oncology

31 CD44-Gal9 Interaction between IDH1-mutant Grade 4 Astrocytoma and Microglia Promotes Invasion and Proliferation of Tumor Cells

Nathalie Große, Felix Sahm, Christel Herold-Mende, Şevin Turcan

Abstract Introduction IDH1-mutant grade 4 astrocytomas exhibit pronounced interactions with the tumor microenvironment that critically influence tumor progression. Tumor-associated microglia/macrophages (TAMs) are key mediators of these interactions, yet the molecular mechanisms governing tumor-TAM crosstalk remain incompletely understood. Here, we investigated the role of CD44-Galectin-9 (Gal9) signaling in patient-derived IDH1-mutant astrocytoma models. Method scRNA-seq was performed on paired primary and recurre …

27.08.2026journal-article

Neuro-Oncology

67 Limited-stage small cell lung cancer – how to address the high risk of intracranial metastases?

Dina Saleh, Waleed Mohammed

Abstract Introduction Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers and is characterised by rapid proliferation, early dissemination and poor prognosis. It has a strong predilection for brain metastases, with around 10% of patients presenting with intracranial disease. Current standard of care recommends prophylactic cranial irradiation (PCI) for patients with limited-stage (LS) SCLC who respond to initial therapy. However, scrutiny of practice in the modern era does not necessarily r …

27.08.2026journal-article

World Journal of Surgical Oncology

Modified Albert–Lembert coloanal anastomosis with diverting ileostomy versus Turnbull–Cutait pull-through delayed coloanal anastomosis after intersphincteric resection for low rectal cancer: a single-center retrospective comparative study

Mengzhe Li, Hong Liang, Xi Wang, Zhanpeng Yang, Longshuai Yang, Gaojie Lian, Jianhui Li, Qingwen Fan, Chao Zhang

Abstract Background Reconstruction after intersphincteric resection (ISR) for low rectal cancer remains technically challenging. Turnbull–Cutait pull-through delayed coloanal anastomosis (DCAA) has been used as a sphincter-preserving delayed reconstructive strategy, but it requires exteriorization of the colon and a planned second-stage perineal procedure. To improve anastomotic stability after ISR, we performed modified Albert–Lembert coloanal anastomosis (MALA) with diverting ileostomy. This study aimed to compar …

27.08.2026journal-article

Cancer Research

Chronic Stress–Induced m7G Cap Modification of ADRB2 Dysregulates the Pentose Phosphate Pathway to Promote Esophageal Squamous Cell Carcinoma Progression

Zihan Zhang, Feifei Liu, Peng Wang, Ting Wang, Xiangyu Wang, Rui Wang, Xiaodan Shi, Ruixia Zou, Ludan Jia, Xing Wei, Zhibo Li, Yankan Yu, HaiBo Sun, Dong Joon Kim, Simin Zhao, Zigang Dong

Abstract Chronic stress is increasingly recognized as a driver of cancer metabolism, highlighting the need to elucidate the mechanism linking chronic stress to metabolic reprogramming. In this study, we performed untargeted metabolomics on serum samples from patients with esophageal squamous cell carcinoma (ESCC) and integrated the results with clinical and stress-related assessments, revealing pentose phosphate pathway (PPP) enrichment accompanied by elevated epinephrine levels in patients with stress-associated f …

27.08.2026journal-article

Cancer Research

A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells

Bo-Reum Kim, Hyemin Kim, Hoon Choi, Daehun Kwag, Yoon-Ju Kim, Hyunsong Son, Sohyun Park, Jisu Park, Hadong Kim, Woosuk Choi, Seunghoon Lee, Hee-Je Kim, Hyunseok Kang, Hyunsun Jo, Byung-Sik Cho

Abstract Casein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degrading target proteins. In this study, we developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in preclinical AML models. PinA1 preferentially degraded CK1α at nanomolar concentrations, resulting in enhanced p53 expression, c …

27.08.2026journal-article

Cancer Medicine

UTMD Suppresses CSF ‐1 to Drive Macrophage‐Mediated Ferroptosis in Papillary Thyroid Carcinoma

Yanqiang Niu, Zhenqiang Yao, Minghua Zhang, Jiayan Zhang, Yushan Li, Jinhui Xie, Zubang Zhou

ABSTRACT The tumor microenvironment (TME) of Papillary Thyroid Carcinoma (PTC), particularly the role of tumor‐associated macrophages (TAMs), contributes to therapeutic resistance. This study investigated whether ultrasound‐targeted microbubble destruction (UTMD), a non‐invasive physical modality, could reprogram the TME through modulation of TAMs and induction of ferroptosis. Transcriptomic profiling identified CSF‐1 as a top target suppressed by UTMD, which was validated by ELISA, Western blot, and qRT‐PCR. UTMD …

27.08.2026journal-article

Molecular Cancer Therapeutics

Structural basis and preclinical efficacy of MG1124, a novel CEACAM1-targeting antibody synergizing with PD-1 blockade

Jae-Chul Lee, Miyoung Oh, Hye-mi Nam, Hyun-Jung Cho, Jae Hwan Kim, Byoung Chul Cho, Seonghoon Kim, Byung-Ha Oh, Chang-Woo Lee

Abstract CEACAM1 homodimerization mediates tumor immune evasion, presenting a compelling target to overcome resistance to PD-1 blockade. However, defining a precise structural and pharmacological blueprint for CEACAM1 targeting has remained challenging. Here, we report the discovery and comprehensive preclinical characterization of MG1124, a highly specific, fully human monoclonal antibody targeting the CEACAM1 IgV domain. X-ray crystallographic analysis at a 1.8 Å resolution revealed that MG1124 binds the homodime …

27.08.2026journal-article

Revista Científica Saúde Global

Strategies in the Prevention and Treatment of Obesity

Ieda Carla Candido, Gisele Nicchio Rocha Buzzo, Matheus Rodrigues Dos Santos, Rafaela Crystina Vieira Bonfim, Fernanda Aparecida Vicente Magalhães, Karine Oltramari, Paulo Cesar Franzini, Angélica Sbrolini Marques Mincache, Greice Westphal-Nardo, Nelson Nardo Júnior Nardo Júnior

Objective: This study aims to present the most recent advances and the challenges encountered in the provision of pharmacological, surgical, and multidisciplinary programs for the treatment of obesity. Methods: This is a narrative literature review with a qualitative and exploratory approach, conducted in July 2025. The theoretical framework was based on studies published between 2020 and 2025, focusing on strategies for obesity prevention and treatment, particularly pharmacological therapies, bariatric surgery, an …

27.08.2026journal-article

BMC Cancer

miR-451a is a differentially expressed blood-based microRNA in newly diagnosed CML identified by high-throughput profiling

Surbhi Gupta, Nitu Nigam, Abdullah H. Maad, Ninar AlJerf, S. P. Verma, Swasti Sinha, Rashmi Kushwaha, Manish Kumar Singh, Arun Kumar Trivedi, Soniya Nityanand, Muaaz Alajlani, Loai Aljerf

Abstract Background microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker. Methodology We collected whole blood samples from 77 newly diagnosed CML patients before TKI therapy and 77 healthy controls. A subset of samples underwent miRNA sequencing to identify dysregulated …

27.08.2026journal-article

Cancer Medicine

Adjusted Risk Stratification of Indeterminate Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI‐RADS)

Jessica Zhao, Rita Abi‐Raad, Sara I. Pai, Jonathan Langdon, Minhua Wang, Guoping Cai, John Sinard, Adebowale J. Adeniran, Sanhong Yu

ABSTRACT Background The TI‐RADS guides the initial management of thyroid nodules, but the malignancy risk across different categories of cytologically indeterminate thyroid nodules (CITNs), particularly AUS and FN, remains unclear. Methods We reviewed thyroid FNA specimens diagnosed as AUS or FN with TI‐RADS scores of 3, 4, or 5 from 2017 to 2025. Clinical data, molecular results, and surgical outcomes were analyzed. Results A total of 919 CITNs were identified: 304 with TI‐RADS 3, 454 with TI‐RADS 4, and 161 with …

27.08.2026journal-article

Neuro-Oncology

58 Disrupting metabolic plasticity in glioblastoma stem-like cells via FABP7 inhibition and DHA supplementation

Cécilia Bernier, Seth Peyton, Cyrene Jonah Catenza, Won-Shik Choi, Abigail Hill, Liang Li, Hélène Lemieux, Roseline Godbout

Abstract Introduction Glioblastoma (GBM) is a brain cancer with high recurrence and poor remission rates despite intensive therapies. Treatment resistance is attributed to GBM stem-like cells (GSCs), which display high metabolic plasticity to adapt to environmental and therapeutic stress. GSCs express high levels of fatty acid-binding protein 7 (FABP7), which facilitates intracellular lipid transport. FABP7 binds docosahexaenoic acid (DHA), a polyunsaturated fatty acid with anti-tumorigenic properties in GSCs. Howe …

27.08.2026journal-article

Neuro-Oncology

14 Writing To Patients With Vestibular Schwannoma Transitioning from complexity to clarity leveraging Learning language model

Hina Kapadia, Andrew Kay, Luke Galloway

Abstract Introduction Effective written communication is central to patient-centred and safe care. NHS guidance recommends that outpatient clinic letters be written directly to patients at a readability level equivalent to Flesch Reading Ease (FRE) ≥60. However, neurosurgical correspondence often remains highly technical. Vestibular schwannoma (VS) management, involving complex decisions regarding surgery, radiotherapy, or surveillance, provides a suitable model to examine readability and evaluate whether large lan …

27.08.2026journal-article

Neuro-Oncology

18 TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial

Gerben Borst, David D Tran, Ashley P Ghiaseddin, Michael Lim, Michael Weller, Motoo Nagane, Jacob C Easaw, Elizabeth Cohen-Jonathan Moyal

Abstract Introduction With the current standard-of-care for glioblastoma (maximal safe resection followed by radiotherapy with concurrent TMZ, then maintenance temozolomide/TTFields), median overall survival (OS) is approximately 21 months. Immune checkpoint inhibitors have not demonstrated meaningful clinical benefit in glioblastoma, partly because the tumor microenvironment is immunosuppressive. Preclinically, TTFields can induce immunogenic cell death and activate type 1 interferon signaling, with downstream inc …